Jim Simons’s Nautilus Biotechnolgy NAUT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.03M Buy
265,700
+5,800
+2% +$14.3K ﹤0.01% 2265
2025
Q4
$507K Sell
259,900
-747,762
-74% -$1.23M ﹤0.01% 2570
2025
Q3
$851K Buy
1,007,662
+387,756
+63% +$285K ﹤0.01% 2568
2025
Q2
$449K Buy
619,906
+319,450
+106% +$240K ﹤0.01% 2888
2025
Q1
$259K Buy
300,456
+50,235
+20% +$74.7K ﹤0.01% 2985
2024
Q4
$420K Buy
250,221
+95,521
+62% +$228K ﹤0.01% 2921
2024
Q3
$441K Buy
154,700
+14,600
+10% +$37.8K ﹤0.01% 2843
2024
Q2
$328K Buy
140,100
+14,100
+11% +$36.8K ﹤0.01% 2876
2024
Q1
$370K Buy
126,000
+9,300
+8% +$26.4K ﹤0.01% 2995
2023
Q4
$349K Sell
116,700
-100
-0.1% -$286 ﹤0.01% 2927
2023
Q3
$369K Buy
116,800
+400
+0.3% +$1.3K ﹤0.01% 2842
2023
Q2
$450K Buy
116,400
+6,200
+6% +$17.9K ﹤0.01% 2928
2023
Q1
$305K Buy
110,200
+10,700
+11% +$22.4K ﹤0.01% 3109
2022
Q4
$179K Buy
99,500
+10,400
+12% +$20.1K ﹤0.01% 3456
2022
Q3
$189K Buy
89,100
+25,500
+40% +$64.1K ﹤0.01% 3403
2022
Q2
$171K Buy
63,600
+52,600
+478% +$196K ﹤0.01% 3704
2022
Q1
$48K Buy
+11,000
New +$45.2K ﹤0.01% 3919

Other funds holding NAUT

Jim Simons's NAUT Position: Q1 2026 in Review

Jim Simons increased its Nautilus Biotechnolgy (NAUT) stake by 2.2% in Q1 2026, buying an estimated $14.3K and bringing the position to 265,700 shares worth $1.03M. The position accounts for ﹤0.01% of the portfolio, ranked #2265.

Jim Simons first reported a position in NAUT in Q1 2022 and has held it in 17 quarters since. 81 funds tracked by Wall St. Rank hold NAUT as of Q1 2026.

  • Jim Simons held 265,700 shares of Nautilus Biotechnolgy worth $1.03M as of Q1 2026.
  • Jim Simons bought 5,800 Nautilus Biotechnolgy shares in Q1 2026, an estimated $14.3K.
  • Nautilus Biotechnolgy made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #2265 holding.
  • Jim Simons first reported a position in Nautilus Biotechnolgy in Q1 2022 and has held it in 17 quarters since.
  • 81 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.